ArticleMalaria journal2025
No evidence of molecular markers of piperaquine resistance in southeastern Nigeria.
Article in Malaria journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundArtemisinin‑based combination therapy (ACT) remains the first‑line treatment for uncomplicated malaria, yet its long‑term efficacy is threatened by Plasmodium falciparum resistance to both artemisinin derivatives and partner drugs. Routine surveillance of clinical efficacy and molecular‑resistance markers is therefore essential. Piperaquine (PPQ), the partner drug in dihydroartemisinin-piperaquine (DHA‑PPQ) is already compromised in Southeast Asia, and key PPQ‑resistance mutations have begun to surface in parts of Africa. No such data are available from Nigeria. Three PPQ‑resistanceassociated singlenucleotide polymorphisms (SNPs)-T93S, H97Y and F145Ilocated in exons 2 and 3 of the P. falciparum chloroquineresistance transporter gene (pfcrt), and copy‑number variation of plasmepsin 2/3 (pfpm2/3), were retrospectively investigated using 299 archived patient isolates collected in Awka (n = 200) and Onitsha (n = 99), South‑East Nigeria (2018-2019).
methodsAllelic states at pfcrt codons 93, 97 and 145 were determined by nested PCR followed by Sanger sequencing. Pfpm2/3 copy number was quantified by real‑time qPCR, using β‑tubulin as the single‑copy reference. All assays incorporated PPQ‑resistant RF7 and wild‑type 3D7 control strains, plus no‑template controls.
resultsHigh‑quality amplification was achieved for 268 of 299 isolates (89.6%). None harboured the pfcrt T93S, H97Y or F145I mutations, and all exhibited single‑copy pfpm2 and pfpm3. Two novel exon‑2 variants (K115I and synonymous L111L) were each detected once (0.4%) and are regarded as neutral polymorphisms without known phenotypic impact.
conclusionsThe complete absence of validated PPQresistance markers indicates that piperaquine remains a viable partner drug in DHA‑PPQ for South‑East Nigeria. Nonetheless, because DHA‑PPQ is increasingly available over the counter, ongoing molecular and therapeutic‑efficacy surveillance is imperative to detect any future emergence of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.